List of Figures
Figure 1-1: Historical Development of Antibody-Drug Conjugate
Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
Figure 2-1: Classification of Antibody-Drug Conjugates
Figure 2-2: Components of Antibody-Drug Conjugates
Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
Figure 2-5: Classification of Linkers
Figure 2-6: Types of Cleavable Linkers
Figure 2-7: Non-Cleavable Linker Used in ADCs Development
Figure 2-8: Cytotoxic drugs used in Antibody Drug Conjugates
Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal & Cancerous Cells
Figure 3-3: Releasing Mechanism of Payloads
Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
Figure 4-1: Therapeutic Index - Antibody Drug Conjugate vs. Cytotoxic Drug
Figure 6-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 6-2: Mylotarg - Approval Year by Region
Figure 6-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), January'2022
Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-5: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 6-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), January'2022
Figure 6-7: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 6-8: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 6-9: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 6-10: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), Janauary'2022
Figure 6-11: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, January'2022
Figure 6-12: US - Adcetris Oprhan Drug Designation Approval Year by Indication
Figure 6-13: US - Adcetris FDA Approval Year by Indication
Figure 6-14: Adcetris - Approval Year by Region
Figure 6-15: Japan - Adcetris FDA Approval Year by Indication
Figure 6-16: Adcetris - Patent Expiration by Region
Figure 6-17: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), January'2022
Figure 6-18: Adcetris - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-19: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 6-20: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), January'2022
Figure 6-21: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 6-22: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), January'2022
Figure 6-23: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), January'2022
Figure 6-24: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 6-25: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), January'2022
Figure 6-26: US - Kadcyla FDA Approval Year by Indication
Figure 6-27: Kadcyla - Approval Year by Region
Figure 6-28: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 6-29: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), January'2022
Figure 6-30: UK - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (GBP/US$), January'2022
Figure 6-31: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-32: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January'2022
Figure 6-33: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 6-34: Besponsa - Approval Year by Region
Figure 6-35: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), January'2022
Figure 636: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-37: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 6-38; Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 6-39: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), January'2022
Figure 6-40: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), January'2022
Figure 6-41: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks)
Figure 6-42: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 6-43: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-44: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region
Figure 6-46: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 6-47: Polivy - Approval Year by Region
Figure 6-48: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), January'2022
Figure 6-49: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), January'2022
Figure 6-50: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-51: Polivy - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
Figure 6-52: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
Figure 6-53: Enhertu - Approval Year by Region
Figure 6-54: US - Polivy FDA Approval Year by Indication
Figure 6-55: UK - Cost of Supply of Enhertu 100mg Intravenous Powder (GBP/US$), January'2022
Figure 6-56: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-57: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
Figure 6-58: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-59: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
Figure 6-60: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 6-61: Padcev - Approval Year by Region
Figure 6-62: US - Padcev FDA Approval & Patent Expiration Year
Figure 6-63: US - Price for Padcev 20mg & 30mg Intravenous Powder for Injection (US$), January'2022
Figure 6-64: Padcev - Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January'2022
Figure 6-65: Padcev - Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)
Figure 6-66: Padcev - Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)
Figure 6-67: US - Trodelvy FDA Approval by Indication
Figure 6-68: Trodelvy - Approval Year by Region
Figure 6-69: Trodelvy - Patent Expiration by Region
Figure 6-70: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-71: Trodelvy - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-72: US - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 6-73: US - Blenrep FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 6-74: Europe - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 6-75: Europe - Cost of Supply of Blenrep 100mg Intravenous Powder (Euro/US$), January'2022
Figure 6-76: Blenrep - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-77: Blenrep - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-78: Blenrep - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-79: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 6-80: US - Zynlonta Orphan Drug Designation & FDA Approval Year
Figure 6-81: Zynlonta - Orphan Drug Designation by Region
Figure 6-82: Zynlonta - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-83: Zynlonta - Recommended Dose for Initial & Subsequent Cycles (mg/kg)
Figure 6-84: Tivdak - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-85: Tivdak - Maximum Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-86: Tivdak - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-87: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 6-88: India - Price for Single Unit of Ujvira 100mg & 160mg Intravenous Powder for Injection (INR/US$), January'2022
Figure 6-89: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100mg Powder for Injection (INR/US$), January'2022
Figure 6-90: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-91: Ujvira - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 6-92: Akalux - Sakigake Designation & PMDA Approval Year
Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2018 - 2021
Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 7-3: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 7-4: Global - Adcetris Annual Sales (US$ Million), 2022 - 2028
Figure 7-5: Global - Padecv Annual Sales (US$ Million), 2019 - 2021
Figure 7-6: Global - Padcev Quarterly Sales (US$ Million), 2021
Figure 7-7: Global - Padcev Quarterly Sales (US$ Million), 2020
Figure 7-8: Global - Padcev Annual Sales (US$ Million), 2022 - 2028
Figure 7-9: Global - Tivdak Annual Sales (US$ Million), 2021 - 2028
Figure 7-10: Global - Polivy Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-11: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-12: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-13: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-14: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 7-15: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-16: Polivy - Quarterly Sales Value by Region (US$/CHF Million), 2021
Figure 7-17: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 7-18: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-19: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-20: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-21: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 7-22: Polivy - Annual Sales Value by Region (%), 2020
Figure 7-23: Polivy - Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 7-24: Global - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-25: US - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-26: Europe - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-27: Japan - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-28: ROW - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-29: Global - Kadcyla Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-30: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-31: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-32: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-33: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-34: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-35: Kadcyla - Quarterly Sales Value by Region (US$/CHF Million), 2021
Figure 7-36: Kadcyla - Quarterly Sales Value by Region (%),2021
Figure 7-37: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-38: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-39: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-40: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-41: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-42: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 7-43: Kadcyla - Annual Sales Value by Region (%). 2020
Figure 7-44: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-45: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-46: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-47: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-48: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-49: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2019
Figure 7-50: Global - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-51: US - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-52: Europe - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-53: Japan - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-54: ROW - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-55: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
Figure 7-56: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-57: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-58: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-59: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-60: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
Figure 7-61: Besponsa - Quarterly Sales by Region (%), 2020
Figure 7-62: Besponsa - Quarterly Sales by Region (%), 2021
Figure 7-63: Global - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-64: US - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-65: Europe - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-66: ROW - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-67: Global - Enhertu Annual Sales (US$ Million), 2020 & 2021
Figure 7-68: Global - Enhertu Quarterly Sales (US$ Million), 2021
Figure 7-69: Global - Enhertu Quarterly Sales (US$ Million), 2020
Figure 7-70: Global - Enhertu Annual Sales (US$ Million), 2022 - 2028
Figure 7-71: Global - Trodelvy Annual Sales (US$ Million), 2020 & 2021
Figure 7-72: Global - Trodelvy Quarterly Sales (US$ Million), 2021
Figure 7-73: Trodelvy - Annual Sales by Region (US$ Million), 2021
Figure 7-74: Trodelvy - Annual Sales by Region (%), 2021
Figure 7-75: Global - Trodelvy Annual Sales (US$ Million), 2022 - 2028
Figure 7-76: Global - Zynlonta Quarterly Sales (US$ Million), Q2 & Q3'2021
Figure 7-77: Global - Zynlonta Annual Sales (US$ Million), 2022 - 2028
Figure 7-78: Global - Blenrep Annual Sales (US$ Million), 2020 & 2021
Figure 7-79: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-80: US - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-81: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-82: Blenrep - Quarterly Sales by Region (Euro/US$ Million), 2021
Figure 7-83: Blenrep - Quarterly Sales by Region (%), 2021
Figure 7-84: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2020
Figure 7-85: Global - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-86: US - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-87: Europe - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-88: ROW - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 8-1: Global - Antibody Drug Conjugate Market (US$ Billion), 2020 & 2021
Figure 8-2: Antibody Drug Conjugate Market Size by Region (US$ Billion), 2021
Figure 8-3: Antibody Drug Conjugate Market Size by Region (%), 2021
Figure 8-4: Global - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-2: US vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-3: US vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-4: US - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-5: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-6: Europe vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-7: Europe vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-8: Europe - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-9: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-10: Japan vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-11: Japan vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-12: Japan - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-13: China - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-14: China vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-15: China vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-16: China - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-17: South Korea - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-18: South Korea vs. ROW - Antibody Drug Conjugate Market (US$ Billion), 2021
Figure 9-19: South Korea vs. ROW - Antibody Drug Conjugate Market (%), 2021
Figure 9-20: South Korea - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-21: India - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-22: India - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-23: Australia - Cancer Incidences & Deaths, 2020 & 2025
Figure 9-24: Australia - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-25: Taiwan - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-26: Canada - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-27: Canada vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-28: Canada vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-29: Canada - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-1: Global - Breast Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-2: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
Figure 10-3: Global - Antibody Drug Conjugate Market by Indication (%), 2021
Figure 10-4: Global - Breast Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-5: Global - Hodgkin & Non-Hodgkin Lymphoma Incidences (Million), 2020 & 2025
Figure 10-6: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
Figure 10-7: Global - Antibody Drug Conjugate Market by Indication (%), 2021
Figure 10-8: Global - Lymphoma Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-9: Global - Leukemia Incidences & Deaths, 2020 & 2025
Figure 10-10: Global - Leukemia Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-11: Global - Multiple Myeloma Incidences & Deaths, 2020 & 2025
Figure 10-12: Global - Multiple Myeloma Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-13: Global - Gastric Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-14: Global - Gastric Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-15: Global - Lung Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-16: Global - Lung Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2023 - 2028
Figure 11-1: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (Numbers), 2022 till 2028
Figure 11-2: Global - Antibody Drug Conjugate Clinical Pipeline by Indication, 2022 till 2028
Figure 11-3: Global - Antibody Drug Conjugate Clinical Pipeline by Company, 2022 till 2028
Figure 11-4: Global - Antibody Drug Conjugate Clinical Pipeline by Patient Segment, 2022 till 2028
Figure 11-5: Global - Antibody Drug Conjugate Clinical Pipeline by Country, 2022 till 2028
Figure 14-1: Antibody Drug Conjugates Market Drivers
Figure 14-2: Challenges for Antibody Drug Conjugates Market